I prva recenica u studiji glasi: "Randomizirane klinicke studije su konsistivno pokazale da (...) statini (lijekovi za obaranje masnoce u krvi) smanjuju broj kardiovaskularnih incidenata."
Da bih izvukao sto vise znanja iz ove studije, preskocio sam ostatak teksta i pogledao paragraf koji navodi autorske mogucnosti sukoba interesa, a on izgleda ovako:
"Supported by AstraZeneca.
Dr. Nicholls reports receiving consulting fees from Roche, Esperion, Merck, Omthera, Sanofi-Aventis, and Boehringer Ingelheim, serving as an unpaid consultant for Abbott, Pfizer, LipoScience, Novo Nordisk, AtheroNova, and CSL Behring, receiving grant support from Eli Lilly, AstraZeneca, Novartis, Anthera, LipoScience, Roche, and Resverlogix and lecture fees from AstraZeneca and Roche; Dr. Ballantyne, receiving grant support from Abbott, AstraZeneca, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Kowa, Merck, Novartis, Roche, Sanofi-Synthelabo, and Takeda, consulting fees and honoraria from Abbott, Adnexus, Amarin, Amylin, AstraZeneca, Bristol-Myers Squibb, Esperion, Genentech, GlaxoSmithKline, Idera, Kowa, Merck, Novartis, Omthera, Resverlogix, Roche, Sanofi-Synthelabo, and Takeda and lecture fees from Abbott, AstraZeneca, GlaxoSmithKline, and Merck; Dr. Barter, holding an advisory board position for AstraZeneca, Merck, Roche, CSL Behring, and Pfizer, receiving grant support from Merck, consulting fees from CSL Behring, and lecture fees from AstraZeneca, Kowa, Merck, Pfizer, and Roche; Dr. Chapman, receiving grant support from Merck and Kowa, consulting fees from Merck and Pfizer, and lectures fees from Merck and Kowa; Dr. Erbel, receiving grant support from the Heinz Nixdorf Foundation and the German Research Foundation and support for travel, accommodations, or meeting expenses from Biotronik, Sanofi, and Novartis; Dr. Libby, serving as an unpaid consultant for Novartis, Johnson & Johnson, Amgen, and Roche, serving in unpaid leadership roles for clinical trials sponsored by AstraZeneca, GlaxoSmithKline, Novartis, Pfizer, Pronova, and Sigma Tau, and having previously received royalties from Roche for the patent on CD40L in cardiovascular risk stratification; Dr. Raichlen, being an employee of and owning stock in AstraZeneca; and Dr. Nissen, receiving consulting fees from Eli Lilly, grant funding from AstraZeneca, Pfizer, Novartis, Karo Bio, Novo Nordisk, Takeda, Resverlogix, and Omthera, and support for travel, accommodations, or meeting expenses from Novo Nordisk, Takeda, Karo Bio, Eli Lilly, Pfizer, Novartis, and Amgen.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
No other potential conflict of interest relevant to this article was reported."
Skromno, nema šta. Dakle, AstraZeneka je podrzala ovu studiju. Treba dodati i da AstraZeneka trenutno prodaje statin po generickom imenu rozuvastatin, a u apotekama pod nazivom Crestor. Crestor je najprofitabilniji lijek AstraZeneke, sa pazarom od 5.7 milijardi dolara u 2010. godini.
Osim sto su na listi sukoba interesa navedene skoro sve najjace farmaceutske kompanije, mozemo izdvojiti i Pfizer, ciji statin Lipitor je najprofitabilniji lijek svih vremena.
....i tako sam ostatak studije ostavio za neke druge generacije i struke da ih citaju. Mozda menadzere to bude vise interesovalo?
NEJM
No comments:
Post a Comment